News

March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German ...
As one of Boehringer Ingelheim's asthma competitors catches ... out-of-pocket costs at $35 per month for all of its inhaler products, including Atrovent, Combivent, Striverdi, Stiolto and its ...
Boehringer Ingelheim is a biopharmaceutical company ... information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press ...
Biosimilar products like this are viewed as critical ... senior vice president of value and access at Boehringer Ingelheim. "Partnering with GoodRx to offer our biosimilar Adalimumab-adbm at ...
Boehringer Ingelheim today announced a continued rise ... “As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal ...
INGELHEIM, Germany ... unlisted drugmaker said in a statement. Sign up here. Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly (LLY.N), opens new tab, made 8.4 ...
The plaintiff further claimed the program is a "physical taking" of its products "without just compensation." The court concluded that Boehringer Ingelheim can opt out of Medicare and Medicaid ...
Boehringer Ingelheim is committed to changing this ... We sell different types of products and services to both investment professionals and individual investors. These products and services ...
Boehringer Ingelheim has taken an option on a family ... that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin (also ...
"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...
Boehringer Ingelheim has released data on its patient reach ... “As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal ...